QPPV.COM KNOWLEDGE ASSESSMENT

Ansuvimab: Classification, Mechanism and Pharmacovigilance — Knowledge Assessment

Test your understanding of the concepts covered by Ansuvimab: Classification, Mechanism and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 An investigator argues that a reaction is unlikely because ansuvimab is fully human. Which response is most consistent with the article?

Human sequence excludes hypersensitivity and infusion-associated reactions. Human sequence describes the antibody’s origin and composition but does not eliminate the need to monitor for hypersensitivity or infusion events. Human sequence means the product has no pharmacological activity in humans. Human sequence establishes safety in all patient populations.

Question 2 of 10 A patient receives ansuvimab during an outbreak. Which statement best describes its place in care?

It is intended to replace isolation and infection-control procedures once administered. It is used alongside outbreak-response measures and supportive care, not as a substitute for them. It removes the need for fluid and organ support if viral entry is blocked. It is intended only after all supportive care has failed.

Question 3 of 10 Which regimen is described in the article as the U.S. regimen?

A single intravenous dose of 50 mg/kg over 60 minutes. A daily oral dose for five days. Two intravenous doses of 25 mg/kg on consecutive days. A single intramuscular dose followed by a maintenance infusion.

Question 4 of 10 Which documentation would best support assessment of a suspected infusion-associated event?

Only the event term and whether it was considered serious. Pre-infusion condition, dose and infusion times, symptom onset, vital signs, findings, interventions, infusion disposition, concurrent therapies, and outcome. Only the patient’s viral test result and the treating clinician’s final diagnosis. Only the time the event was reported to the safety team.

Question 5 of 10 A patient shows no clinical improvement after ansuvimab. Which assessment best follows the article’s pharmacovigilance approach?

Conclude that the medicine failed because the antibody blocks viral entry. Assess disease severity, treatment delay, susceptibility information if available, other therapies, and the clinical team’s assessment. Conclude that the virus was resistant even if no susceptibility information exists. Exclude the outcome from safety reporting because lack of response is not a clinical outcome.

Question 6 of 10 Which statement best distinguishes ansuvimab’s antiviral mechanism from management of established Ebola disease?

Blocking viral entry directly reverses existing organ dysfunction, so supportive care is optional. Blocking viral entry is an antiviral action, while existing disease manifestations may still require supportive and organ care. Supportive care is required only if ansuvimab cannot bind the virus. The antibody acts by treating symptoms rather than targeting the virus.

Question 7 of 10 Which statement reflects the WHO guidance described in the article?

Ansuvimab and REGN-EB3 should routinely be administered together. WHO recommends mAb114 or REGN-EB3 for Ebola virus disease caused by Zaire ebolavirus, and the two treatments should not be given together. WHO recommends ansuvimab for all Orthoebolavirus and Orthomarburgvirus species. WHO guidance takes precedence over later applicable outbreak guidance in all circumstances.

Question 8 of 10 An outbreak report lacks reliable records for the exact onset time of a symptom. What is the most appropriate reporting practice?

Estimate the time from memory so that the chronology appears complete. State that the timing is unknown rather than infer a chronology that the records do not support. Assume the symptom began during infusion if it was reported afterward. Omit the symptom because its onset time is uncertain.

Question 9 of 10 Which statement correctly relates ansuvimab’s research history to current safety monitoring?

Its isolation from an Ebola survivor means hypersensitivity monitoring is unnecessary. Its earlier name was mAb114, and its human origin does not remove the need to monitor for infusion-associated events. Its survivor-derived origin establishes effectiveness against all viral variants. Its research name indicates that it is a mixture of monoclonal antibodies.

Question 10 of 10 A patient develops hypotension during ansuvimab infusion, but hypotension was also present before treatment. Which additional information is most useful for assessing a possible infusion reaction?

Whether blood pressure worsened or changed in relation to infusion, the associated clinical pattern, interventions, and alternative explanations. Whether hypotension appears in the product label, without further case details. Whether the patient’s family considers the event medicine-related. Whether the infusion was completed, as completion excludes a reaction.

QPPV.com

Ansuvimab: Classification, Mechanism and Pharmacovigilance — Knowledge Assessment

Cookie Settings